Pacira Biosciences Inc banner

Pacira Biosciences Inc
NASDAQ:PCRX

Watchlist Manager
Pacira Biosciences Inc Logo
Pacira Biosciences Inc
NASDAQ:PCRX
Watchlist
Price: 24.51 USD -3.35% Market Closed
Market Cap: $992.4m

Pacira Biosciences Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Pacira Biosciences Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Pacira Biosciences Inc
NASDAQ:PCRX
Revenue
$726.4m
CAGR 3-Years
3%
CAGR 5-Years
11%
CAGR 10-Years
11%
Johnson & Johnson
NYSE:JNJ
Revenue
$96.4B
CAGR 3-Years
8%
CAGR 5-Years
3%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$48.2B
CAGR 3-Years
1%
CAGR 5-Years
3%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$62.6B
CAGR 3-Years
-15%
CAGR 5-Years
8%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Revenue
$65B
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Revenue
$65.2B
CAGR 3-Years
32%
CAGR 5-Years
22%
CAGR 10-Years
13%
No Stocks Found

Pacira Biosciences Inc
Glance View

Market Cap
992.4m USD
Industry
Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 697 full-time employees. The company went IPO on 2011-02-03. The firm is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain. Its iovera is a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

PCRX Intrinsic Value
80.89 USD
Undervaluation 70%
Intrinsic Value
Price $24.51

See Also

What is Pacira Biosciences Inc's Revenue?
Revenue
726.4m USD

Based on the financial report for Dec 31, 2025, Pacira Biosciences Inc's Revenue amounts to 726.4m USD.

What is Pacira Biosciences Inc's Revenue growth rate?
Revenue CAGR 10Y
11%

Over the last year, the Revenue growth was 4%. The average annual Revenue growth rates for Pacira Biosciences Inc have been 3% over the past three years , 11% over the past five years , and 11% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett